Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference.
Rhea-AI Summary
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management will engage in a fireside chat on February 6, 2025, at 10:30 a.m. ET.
The event will be accessible through a live webcast, for which registration is required. The presentation will also be available on the company's website in the Investors section under Events & Presentations, with the archived version remaining accessible for approximately 90 days after the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – VIGL
The recorded move for VIGL in the trading session of this news was +7.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.